On February 3, 2022, Chardan hosted a leadership call with CytoImmune's leadership including Christina Coughlin, MD, PhD, CEO; Michael Caligiuri, MD, CMO; and Aleksey Krylov, CFA, CFO. Chardan Senior Research Analyst Keay Nakae moderated.

CytoImmune is a company developing NK cell therapies for solid tumors and blood cancers. The company has developed the proprietary TRACK-NK platform that is designed to produce a highly activated and tumor-reactive NK cell product. The lead program, CYTO NK-102 is slated to begin clinical trials in non-small cell lung cancer (NSCLC) in 2022 with monotherapy expected in the 2nd half of the year. CytoImmune also plans to evaluate CYTO NK-102 in combination with a PD-L1 inhibitor in NSCLC, and has a pipeline of preclinical-stage engineered CAR-NK assets.

Watch the replay of this event.